1d) and further decreased blood glucose (Fig
doi: 10.1681/asn.2014121271 119 SunHGuoYWangHYinAHuJYuanTet al
The STEP (Semaglutide Treatment Effect in People with obesity) 1 trial was a randomized, placebo-controlled trial that evaluated the efficacy of once-weekly subcutaneous (SC) semaglutide 2.4 mg plus lifestyle interventions in adults with obesity without diabetes (n = 1961)
Microdosing GLP-1s is hardly a one-size fits all process, and its important to use a telehealth platform that offers a truly personalized plan
UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price
doi: 10.3390/cells11162587 25 BjornholmKDPovlsenGKOugaardMEPykeCRakipovskiGTveden-NyborgPet al
